Inspire Pharmaceuticals (ISPH) Tops Q4 EPS by 6c, Guides In-line for FY Revenues
More News related to ISPH
- Inspire Pharma (ISPH) posts Q3 Loss of $0.12, Bests By 3c
- Inspire Reports Third Quarter 2009 Financial Results
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Inspire Completes Patient Enrollment in Three Late-Stage Clinical Trials in Cystic Fibrosis, Dry Eye and Blepharitis
- Inspire Announces Date for Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results
More News related to Earnings
- Communications Systems (JCS) Reports Year-Over-Year Decline in Q3 Earnings
- Communications Systems (JCS) Posts Q3 EPS of $0.22, Down Y/Y
- Atmos Energy (ATO) Posts Q4 Loss of $0.17, Wider than Estimates
- China Digital TV (STV) Misses Q3 EPS by 2c; Guides Below for Q4
- Ralcorp (RAH) Misses Street's Q4 Views; Announces 7M Share Buyback
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) reports a Q4 loss of $0.37, 6 cents better than estimates. Revenues were $8.5 million vs. $8.78 million consensus.
Based upon current Elestat and Restasis trends and projected operating plans, Inspire expects to record aggregate revenue in the range of $40-$47 million and expects operating expenses to be in the range of $90-$112 million in 2007. (FY07 revenue consensus is $45.53 million)
Related Categories
EarningsGuidance
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
